Comparison

创美e药 vs 诺民疾病模型

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

创美e药

Features
Read full description

创美e药,是隶属于创美药业的为创美用户度身定制的一款B2B商城APP。让您随时随地拥有药品、医疗器械、食品与保健品、化妆品等搜索、浏览、购买、收藏以及咨询等功能。众多商品随手掌握。

About

诺民疾病模型

Features
Read full description

本应用为诺民卫生疾病模型。该模型展示了如何利用模型输入参数,通过友好界面实时展示成本效益分析和预算分析结果。该模型具备以下功能: 1. 成本效益分析; 2. 预算影响分析; 3. 疾病负担; 4. 产品定价; 5. 市场预测; 6. 客户沟通工具。

Screenshots

创美e药4 screens
诺民疾病模型4 screens

Verdict

The call

The clearest difference is iOS requirement: 诺民疾病模型 at 9.0 against 创美e药's 15.0. On price, update cadence, ads and in-app purchases there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. Neither carries in-app purchases, so what you see is what you pay.

UpkeepUpdate frequency

创美e药 ships an update every 5 weeks, 诺民疾病模型 every 3 weeks. The most recent releases landed on November 2, 2026 and October 26, 2026 respectively.

Scorecard1 real difference · 5 level
创美e药 versus 诺民疾病模型: the parameters behind the verdict, then further details
Parameter创美e药诺民疾病模型
PriceFreeFree
Update frequencyEvery 5 weeksEvery 3 weeks — better
AdsNoNo
In-app purchasesNoNo
DevicesiPhone, iPodiPhone, iPad, iPod — better
Requires iOS15.09.0 — better
Further details — not scored
Size34 MB15 MB
Age rating12+12+
Developer创美药业长沙诺民医疗科技有限公司

In-app purchases

None

创美e药

No in-app purchases

None

诺民疾病模型

No in-app purchases

Questions

Is 创美e药 free?
创美e药 is free to download, with no in-app purchases.
Is 诺民疾病模型 free?
诺民疾病模型 is free to download, with no in-app purchases.
Do 创美e药 or 诺民疾病模型 have ads?
Neither 创美e药 nor 诺民疾病模型 shows ads.
Which is updated more often, 创美e药 or 诺民疾病模型?
创美e药 ships an update every 5 weeks, and 诺民疾病模型 every 3 weeks. Most recently, 创美e药 was updated on November 2, 2026 and 诺民疾病模型 on October 26, 2026.

Other comparisons